Sertraline (Oral Antidepressant)

DRUG9 trials

Sponsors

Janssen Research & Development, LLC, Nishtar Medical University, Emine Kanmaz, Biruni University

Conditions

Depressive Disorder, Treatment-ResistantEnd Stage Renal Disease on Hemodialysis (Diagnosis)HemodialysisInflamationPremature EjaculationSocial Anxiety DisorderTreatment-resistant Depression

Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

CompletedNCT02417064

Janssen Research & Development, LLCTreatment-resistant Depression

Start: 2015-08-10End: 2018-02-20Updated: 2025-04-29

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

CompletedNCT02418585

Janssen Research & Development, LLCTreatment-resistant Depression

Start: 2015-08-07End: 2017-11-06Updated: 2025-04-29

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

CompletedNCT02422186

Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant

Start: 2015-08-20End: 2017-08-10Updated: 2025-04-29

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

CompletedNCT02493868

Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant

Start: 2015-10-01End: 2018-02-16Updated: 2025-04-29

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

CompletedNCT02497287

Janssen Research & Development, LLCTreatment-resistant Depression

Start: 2015-09-30End: 2017-10-28Updated: 2025-04-29

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

CompletedNCT03434041

Janssen Research & Development, LLCDepressive Disorder, Treatment-Resistant

Start: 2018-05-25End: 2021-04-13Updated: 2025-04-29

Phase 4

Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder

RecruitingNCT07192367

Emine KanmazSocial Anxiety Disorder

Start: 2024-11-15End: 2026-12-31Target: 56Updated: 2025-09-25

Unknown Phase

Effect of Sertraline on Inflammation in Hemodialysis Patients with Depression: a Randomized Controlled Trial

Active, not recruitingNCT06840379

Nishtar Medical UniversityEnd Stage Renal Disease on Hemodialysis (Diagnosis), Hemodialysis, Inflamation

Start: 2024-10-15End: 2025-04-15Updated: 2025-03-04

Dorsal Penile Nerve Cryoneurolysis for Lifelong PE

CompletedNCT07879105

Biruni UniversityPremature Ejaculation

Start: 2026-02-04End: 2026-05-25Updated: 2026-10-16

Related Papers

Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.

2026-02-12

Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.

2025-10-30

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study

The International Journal of Neuropsychopharmacology2025-05-0412 citations

Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study

Frontiers in Psychiatry2024-10-073 citations

Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery–Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire

CNS Spectrums2024-04-014 citations

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry2023-10-316 citations

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry

Frontiers in Psychiatry2023-10-314 citations

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

2023-08-0912 citations

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.

2023-05-086 citations

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.

2023-03-3124 citations

Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray

Psychiatry Research2023-03-1516 citations

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

The International Journal of Neuropsychopharmacology2022-12-1411 citations

Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability

Journal of Affective Disorders2022-10-2017 citations

Longitudinal Course of Adverse Events With Esketamine Nasal Spray

The Journal of Clinical Psychiatry2022-09-1614 citations

Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.

2022-04-209 citations

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression

The International Journal of Neuropsychopharmacology2022-01-0552 citations

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Archives of Women s Mental Health2022-01-0131 citations

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

2021-07-2224 citations

Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response

The Journal of Clinical Psychiatry2021-07-1621 citations

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.

2021-07-0714 citations

13 more papers not shown